Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for <i>EGFR</i>-mutated advanced non-small-cell lung cancer: a phase 1b trial.

Journal for immunotherapy of cancer·2026

Same author

Pulmonary nodule prediction in the multi-omics era: integrating radiomics, AI, liquid biopsy, and airway classifiers.

Critical reviews in oncology/hematology·2026

Same author

<i>FLI1</i> enhances the malignant phenotype of glioma cells and exerts immunomodulatory effects through feedback crosstalk with exonic circRNA <i>FECR1</i> and interferon‑induced <i>ISG15</i>.

International journal of molecular medicine·2026

Same author

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

Experimental hematology & oncology·2026

Same author

Tumor-enriched circRNA TAFCR1 drives cancer progression and metastasis by disrupting UBE1-dependent TRIM21-mediated CD44 ubiquitination.

Biomarker research·2026

Same author

Metabolic Vulnerability, Genetic Susceptibility and Risk of Hypertension: UK Biobank Cohort Analysis.

The British journal of nutrition·2026

Search research articles

Related Experiment Video

Updated: Dec 30, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Challenges of evaluating immunotherapy efficacy in solid tumors.

Rilan Bai¹, Wenqian Li¹, Nawen Du¹

¹Cancer Center, the First Hospital of Jilin University, Jilin 130021, China.

Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu

|January 18, 2020

Summary

Immunotherapy shows promise for various cancers, leading to unique response patterns. New evaluation methods are needed to accurately assess treatment efficacy beyond tumor size, incorporating survival data for better outcomes.

Keywords:

Neoplasms immunotherapy milestone analysis pseudoprogression response evaluation criteria

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Experiment Videos

Last Updated: Dec 30, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Area of Science:

Oncology
Immunology
Clinical Trial Methodology

Background:

Immunotherapy offers significant clinical benefits and durable responses across multiple tumor types.
Unique immune-related clinical response patterns emerge with immunotherapy, differing from cytotoxic agents.
Challenges exist in evaluating immunotherapy efficacy, particularly concerning tumor size and long-term survival.

Purpose of the Study:

To review current immune-related response criteria for evaluating immunotherapy efficacy in solid tumors.
To discuss the limitations of imaging-based assessments in capturing immunotherapy response heterogeneity.
To explore survival-based evaluation methods as complementary tools for immunotherapy trials.

Main Methods:

Analysis of existing immune-related Response Criteria (irRC, irRECIST, iRECIST, imRECIST).
Review of survival-based evaluation methods, including milestone analysis and restricted mean survival time.
Discussion on the identification of response patterns like pseudoprogression and hyperprogressive disease.

Main Results:

Current immune-related criteria can identify response heterogeneity, including pseudoprogression and hyperprogressive disease.
Imaging-based assessments have limitations in fully evaluating immunotherapy efficacy.
Survival-based methods, such as milestone analysis, complement conventional survival measures.

Conclusions:

Established immune-related criteria aid in assessing immunotherapy response patterns but have limitations.
Survival-based evaluations are valuable complementary tools for interpreting immunotherapy trial results.
A standardized gold-standard evaluation method is needed to improve imaging and survival-based efficacy assessment in solid tumors.